Clinical Trials Using Rucaparib Camsylate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Rucaparib Camsylate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-11 of 11
  • Rucaparib Camsylate and Radiation Therapy in Treating Patients with Triple Negative Breast Cancer

    This phase I trial studies the side effects and best dose of rucaparib camsylate when given together with radiation therapy in treating patients with triple negative breast cancer. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving rucaparib camsylate and radiation therapy may work better in treating patients with triple negative breast cancer.
    Location: 7 locations

  • Rucaparib and Nivolumab in Treating Patients with Advanced or Metastatic Biliary Tract Cancer after Platinum Therapy

    This phase II trial studies how well rucaparib and nivolumab work in treating patients with biliary tract cancer that has spread to other places in the body after platinum therapy. Rucaparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving rucaparib and nivolumab after platinum therapy may help kill more cancer cells that are left after chemotherapy.
    Location: 3 locations

  • Rucaparib in Treating Patients with Stage III, IV or Endometrial Cancer That Has Either Spread or Has Come Back After Prior Treatment

    This phase II trial studies how well rucaparib works in treating patients with stage III or IV endometrial cancer that has either spread or has come back after prior treatment. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Rucaparib and Pembrolizumab Maintenance Therapy in Treating Patients with Stage IV Non-squamous Non-small Cell Lung Cancer

    This phase I / II trial studies how well rucaparib and pembrolizumab works as maintenance therapy (therapy meant to help primary therapy succeed and to help keep cancer from coming back) in treating patients with stage IV non-squamous non-small cell lung cancer. Rucaparib blocks an enzyme in cells called PARP; in tumor cells, this leads to increased cell death. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving rucaparib and pembrolizumab as maintenance therapy may work better in treating patients with non-squamous non-small cell lung cancer compared to maintenance therapy with pembrolizumab and a chemotherapy drug called pemetrexed.
    Location: 2 locations

  • Rucaparib in Treating Patients with Stage I-III Triple Negative Breast Cancer

    This early phase I trial studies how well rucaparib works in treating patients with stage I-III triple negative breast cancer. Rucaparib is a poly adenosine diphosphate [ADP]-ribose polymerase (PARP) inhibitor. PARPs are proteins that play an important role in the life of a cell and act as a repair crew to help fix broken or damaged deoxyribose nucleic acid strands, allowing the cell to live. However, in cancer cells PARPs can allow the cells to remain alive, grow, and divide. Rucaparib may stop the growth of tumor cells by blocking PARPs needed for cell growth. Giving rucaparib for a short duration may allow doctors to assess changes in the patients' tumor, which can help determine who might benefit from such therapy and potentially immunotherapy in the future.
    Location: Banner University Medical Center - Tucson, Tucson, Arizona

  • Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back. Drugs such as mirvetuximab soravtansine are antibodies linked to a toxic substance and may help find certain tumor cells and kill them without harming normal cells. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving mirvetuximab soravtansine and rucaparib camsylate may work better in treating participants with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients with Metastatic Castration Resistant Prostate Cancer with Homologous Recombination DNA Repair Deficiency

    This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. Chemotherapy drugs, such as docetaxel and carboplatin, work to stop the growth of cancer cells by stopping them from dividing or spreading. Rucaparib camsylate may stop the growth of tumor cells with defects in the ability to repair mistakes in DNA by forcing additional errors so that the cancer cells cannot overcome the number of errors and will then die. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Rucaparib Camsylate in Treating Patients with Metastatic Prostate Cancer

    This phase II trial studies how well rucaparib camsylate works in treating participants with prostate cancer that has spread to other places in the body. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Rucaparib Camsylate and Irinotecan Hydrochloride in Treating Patients with Advanced Solid Tumors with Mutations in DNA Repair

    This phase I trial studies the side effects and best dose of rucaparib camsylate and irinotecan hydrochloride in treating patients with solid tumors with mutations in deoxyribonucleic acid (DNA) repair that have spread to other places in the body (advanced). Rucaparib camsylate and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • CASPAR, A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

    This phase III trial compares the addition of rucaparib to enzalutamide with enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistant to androgen-deprivation therapy. Testosterone is a hormone made mainly in the testes and is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. It also plays role in prostate cancer development. Enzalutamide may help fight prostate cancer by blocking the use of testosterone by the tumor cells for growth. PARPs are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as rucaparib, can keep PARPs from working , so tumor cells can't repair themselves. This may stop tumor cells from growing. Giving enzalutamide and rucaparib may prolong patients’ survival and / or prevent their cancer from growing or spreading for a longer time. It may also help doctors learn if a mutation in any of the specific DNA repair (homologous recombination) genes is helpful in selecting the most appropriate treatment for the patient.
    Location: Location information is not yet available.

  • Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)

    This expansion of the screening and multi-sub-study Lung-MAP trial is motivated by the changing landscape due to progress in the development of immunotherapies. The Lung-MAP trial was originally opened in June of 2014 for second-line treatment of participants with stage IV squamous lung cancer or squamous lung cancer that has come back (recurrent). The trial was amended to allow all participants with previously-treated stage IV or recurrent squamous lung cancer in 2015. The study is now expanding to allow participants with all types of previously-treated stage IV or recurrent non-small cell lung cancer. The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned in order to compare new targeted cancer therapy designed to block the growth and spread of cancer, with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes “non-match” sub-studies which will include all screened participants not eligible for any of the biomarker-driven sub-studies.
    Location: 784 locations